Traphaco JSC - Asset Resilience Ratio

Latest as of March 2026: 21.64%

Traphaco JSC (TRA) has an Asset Resilience Ratio of 21.64% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See TRA current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

₫521.51 Billion
≈ $19.81 Million USD Cash + Short-term Investments

Total Assets

₫2.41 Trillion
≈ $91.56 Million USD All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio Trend (2019–2025)

This chart shows how Traphaco JSC's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see total assets of Traphaco JSC.

Liquid Assets Composition Over Time

This chart breaks down Traphaco JSC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read TRA current and long-term liabilities for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₫0.00 0%
Short-term Investments ₫521.51 Billion 21.64%
Total Liquid Assets ₫521.51 Billion 21.64%

Asset Resilience Insights

  • Good Liquidity Position: Traphaco JSC maintains a healthy 21.64% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company has significant short-term investments, indicating active treasury management.

Traphaco JSC Industry Peers by Asset Resilience Ratio

Compare Traphaco JSC's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Torrent Pharmaceuticals Limited
NSE:TORNTPHARM
Drug Manufacturers - Specialty & Generic 2.79%
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
Drug Manufacturers - Specialty & Generic 1.54%
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
Drug Manufacturers - Specialty & Generic 0.20%
Beijing Tongrentang Co Ltd
SHG:600085
Drug Manufacturers - Specialty & Generic 2.51%
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
Drug Manufacturers - Specialty & Generic 3.47%
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
Drug Manufacturers - Specialty & Generic 20.44%
Harbin Pharmaceutical Group Co Ltd
SHG:600664
Drug Manufacturers - Specialty & Generic 0.97%
Kangmei Pharmaceutical Co Ltd
SHG:600518
Drug Manufacturers - Specialty & Generic 0.00%

Annual Asset Resilience Ratio for Traphaco JSC (2019–2025)

The table below shows the annual Asset Resilience Ratio data for Traphaco JSC.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 22.80% ₫529.51 Billion
≈ $20.12 Million
₫2.32 Trillion
≈ $88.24 Million
-1.26pp
2024-12-31 24.06% ₫521.79 Billion
≈ $19.82 Million
₫2.17 Trillion
≈ $82.41 Million
+4.52pp
2023-12-31 19.54% ₫415.03 Billion
≈ $15.77 Million
₫2.12 Trillion
≈ $80.70 Million
+1.68pp
2022-12-31 17.86% ₫324.33 Billion
≈ $12.32 Million
₫1.82 Trillion
≈ $69.01 Million
+1.15pp
2021-12-31 16.70% ₫285.13 Billion
≈ $10.83 Million
₫1.71 Trillion
≈ $64.86 Million
+10.19pp
2020-12-31 6.51% ₫107.49 Billion
≈ $4.08 Million
₫1.65 Trillion
≈ $62.72 Million
+5.59pp
2019-12-31 0.92% ₫14.50 Billion
≈ $550.91K
₫1.57 Trillion
≈ $59.71 Million
--
pp = percentage points

About Traphaco JSC

VN:TRA Vietnam Drug Manufacturers - Specialty & Generic
Market Cap
$58.27 Million
₫1.53 Trillion VND
Market Cap Rank
#21429 Global
#159 in Vietnam
Share Price
₫37000.00
Change (1 day)
+1.23%
52-Week Range
₫36300.00 - ₫81700.00
All Time High
₫103027.02
About

Traphaco Joint Stock Company, together with its subsidiaries, produces and trades in pharmaceutical products, chemicals, and medical supplies and equipment in Vietnam. The company offers medical supplies; antipyretics; medicines for the hair, eyes, central neutral system, respiratory system, and liver; and other products. It is also involved in the production of medicines to treat human diseases,… Read more